PIK3CA Gene Function
Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha
Overview
PIK3CA encodes p110α, with activating hotspot mutations in ~30% of HR+ breast cancers and ~20% of endometrial and colorectal cancers — among the most common oncogenic mutations across solid tumours. H1047R (kinase domain) and E545K/E542K (helical domain) constitutively generate PIP3, driving AKT/mTOR-dependent survival without upstream receptor input. Alpelisib (PI3Kα-selective) + fulvestrant improved PFS by 5.3 months in PIK3CA-mutant HR+ breast cancer (SOLAR-1, HR 0.65); mechanism-based hyperglycaemia (64% of patients) is the primary toxicity. Resistance via PTEN loss, AKT amplification, and RTK bypass drives development of pan-PI3K/mTOR inhibitors (gedatolisib) and AKT inhibitor combinations.
Molecular Mechanism
Mechanism Summary
PIK3CA hotspot mutations H1047R (kinase domain, ~40% of PIK3CA mutations), E545K and E542K (helical domain, ~20% each) constitutively activate p110α lipid kinase activity through distinct structural mechanisms: H1047R enhances membrane engagement to increase local PIP3 production, while E545K/E542K relieve inhibitory electrostatic contacts from the p85 regulatory subunit. Constitutive PIP3 generation drives AKT/mTOR-dependent cell survival and proliferation signalling without upstream receptor input. Alpelisib (PI3Kα-selective) combined with fulvestrant improved PFS by 5.3 months in PIK3CA-mutant HR+ breast cancer (SOLAR-1, HR 0.65), with mechanism-based hyperglycaemia as the primary toxicity affecting ~64% of patients.
Step-by-Step Mechanism
Membrane-localised p110α catalyses phosphorylation of PIP2 (phosphatidylinositol-4,5-bisphosphate) at the D3 position to generate PIP3 (phosphatidylinositol-3,4,5-trisphosphate).
KRAS-GTP directly binds p110α RBD domain, providing an RTK-independent activation input. This RAS→PI3K axis explains why KRAS mutations confer PI3K pathway activation even without RTK overexpression.
H1047R mutation (in the kinase domain C-lobe) and E545K/E542K mutations (in the helical domain) constitutively activate p110α by different mechanisms: H1047R enhances membrane association and catalysis; E545K/E542K relieve p85-mediated inhibition.
PTEN opposes PI3Kα by dephosphorylating PIP3→PIP2. In PTEN-intact cells, PI3K and PTEN maintain PIP3 at low basal levels. PIK3CA mutations or PTEN loss disrupt this balance toward constitutive PIP3 accumulation.
Upstream Regulators
Maintains p110α in low-activity state; SH2 domains recruit complex to pTyr motifs on RTKs
Binds p110α RBD directly, providing receptor-independent activation
Phosphotyrosines recruit p85 SH2 domains, relieving p110α inhibition
Downstream Targets
Second messenger generation; AKT and PDK1 membrane recruitment
Survival, growth, metabolism, cell cycle
Protein synthesis, autophagy suppression, metabolic reprogramming
Key Post-Translational Modifications
Enhanced membrane affinity, constitutive PIP3 production
Disrupts p85-mediated inhibitory contacts, constitutive activation
Disease Mechanism
PIK3CA hotspot variants can increase PI3Kα activity, but prevalence and predictive meaning vary by tumour lineage. PI3Kα inhibition has indication-specific evidence in biomarker-selected breast cancer and produces mechanism-based metabolic effects such as hyperglycaemia; prevention and management belong in the current label and clinician-led plan. Resistance can involve PTEN loss, parallel RAS–MAPK signalling, receptor reactivation or downstream pathway recovery. ctDNA can detect PIK3CA variants in some settings, but a change in allele fraction is not a universal stand-alone progression rule.
Database References
Key Pathways
- ·PI3K-AKT-mTOR signaling
- ·Insulin signaling
- ·ErbB/EGFR signaling
- ·PI3K inhibitor resistance
Disease Associations
- ·HR+ breast cancer
- ·Endometrial cancer
- ·Colorectal cancer
- ·Head and neck squamous cell carcinoma
Research Activity
PIK3CA is an actively studied target: about 50+ clinical trials that mention it are currently recruiting on ClinicalTrials.gov. Trial activity reflects research interest, not proven benefit — designs, endpoints and populations vary widely.
Track PIK3CA trials
New and changed oncology trials, summarised in plain language each day.
Functional Partners
Common Questions About PIK3CA
What is a PIK3CA mutation?
PIK3CA encodes the p110α catalytic subunit of PI3Kα. Hotspot mutations at H1047R, E542K, and E545K constitutively activate lipid kinase activity, generating PIP3 and driving AKT/mTOR signalling without upstream receptor input. These are gain-of-function oncogenic mutations.
In which cancers are PIK3CA mutations common?
PIK3CA hotspot mutations occur in ~30% of HR+ breast cancers, ~20% of endometrial cancers, ~20% of head and neck cancers, and ~15% of colorectal cancers. They are among the most common oncogenic mutations across solid tumours.
Can PIK3CA mutations be targeted with drugs?
Alpelisib is a PI3Kα-selective inhibitor approved in combination with endocrine therapy for PIK3CA-mutant HR+/HER2− breast cancer, improving progression-free survival in a biomarker-selected population. Resistance typically develops through KRAS mutations or receptor tyrosine kinase amplification.
What is the structural difference between H1047R and E545K PIK3CA mutations?
H1047R is located in the kinase domain C-lobe (exon 20) and activates p110α by increasing membrane binding affinity — the arginine residue enhances electrostatic interaction with the negatively charged phospholipid bilayer, positioning p110α for more efficient PIP2 phosphorylation. E545K and E542K are in the helical domain (exon 9) and activate p110α by disrupting an inhibitory electrostatic interaction between the helical domain and the nSH2 domain of p85 regulatory subunit — the substitution of lysine for glutamate removes the charge-charge repulsion that normally keeps p110α partially inhibited. Both mutation types constitutively activate lipid kinase activity but through distinct structural mechanisms, which may have implications for inhibitor sensitivity profiles.
Why does alpelisib cause hyperglycaemia and how is it managed?
Hyperglycaemia is an on-target mechanism-based toxicity of alpelisib: PI3Kα is essential for insulin receptor signalling in skeletal muscle and adipose tissue, where insulin normally activates PI3K→AKT→GLUT4 translocation to drive glucose uptake. Alpelisib inhibits this pathway in normal insulin-responsive tissues simultaneously with inhibiting it in PIK3CA-mutant tumour cells, reducing peripheral glucose uptake and increasing hepatic glucose output. The result is glucose elevations in ~64% of patients, with grade 3–4 hyperglycaemia in ~37%. Management includes pre-treatment fasting glucose assessment, prophylactic metformin (reduces severity and discontinuation rates), dietary carbohydrate restriction, and insulin/oral hypoglycaemic agents if needed. Hyperglycaemia is the primary dose-limiting toxicity driving treatment discontinuation.
What combination strategies are being tested to overcome PIK3CA inhibitor resistance?
Several approaches address the primary resistance mechanisms to alpelisib: (1) Gedatolisib (pan-PI3K/mTOR inhibitor) + palbociclib + endocrine therapy — the VIKTORIA-1 phase III trial showed superior PFS by simultaneously blocking PI3K, mTOR, and the CDK4/6-driven G1 bypass that emerges during PI3K pathway inhibition. (2) CDK4/6 inhibitors (palbociclib, ribociclib) + alpelisib — combining PI3K inhibition with cell cycle blockade to prevent G1 re-entry from compensatory cyclin D1 stabilisation. (3) AKT inhibitors (capivasertib) for patients with concurrent PTEN loss who may not respond optimally to PI3Kα-selective agents. (4) EGFR/HER2 targeted therapy for resistance mediated by RTK amplification-driven compensatory PI3K activation.